The natural history of treated Parkinson's disease in an incident, community based cohort

Abstract

Background Our understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis. Methods A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and HoehneYahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr'aphic, clinical and genetic variables was evaluated using survival analysis. Results Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (HoehneYahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life. Conclusions Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

“…However it has been proposed that identifying effects which delay the development of major milestones such as dementia, would be a more useful approach [17]. In our trial, cognitive decline was measured with Mattis DRS-2 scale during the on medication state at every time point.…”

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers

“…Its incidence increases with age, 11 and its burden will double over the next generation. 12 Individuals have Parkinson's disease for approximately 14-16 years after diagnosis, 13,14 and it leads to progressive disability, cognitive impairment, limited mobility, 15 and impaired driving ability. 16 Parkinson's disease also burdens caregivers, 17 frequently requires institutional care, [18][19][20] generates high healthcare costs, 21,22 and benefits from specialty care.…”

Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients

“…Mild cognitive impairment (MCI) can be observed since the onset of Parkinson's disease (PD) [1,3] , representing the initial phase of PD cognitive impairment and an important risk factor for the development of Parkinson's-associated dementia (PD-D) [4] .…”